[
  {
    "question": "Parkinson patient came with increase hallucination and memory loss, what is the Rx?",
    "option_a": "Rivastigmin",
    "option_b": "clozapine",
    "option_c": "quetiapin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease patients often develop cognitive impairment and visual hallucinations as part of Parkinson\u2019s disease dementia (PDD). Cholinesterase inhibitors, such as rivastigmine, are used to mitigate these cognitive and behavioral symptoms. In PDD, the accumulation of Lewy bodies leads to a cholinergic deficit in the cerebral cortex. This deficit contributes to both memory impairment and hallucinations. By inhibiting the breakdown of acetylcholine, rivastigmine helps to enhance cholinergic neurotransmission, thereby improving cognitive function and reducing hallucinations. The reported increase in hallucinations and memory loss in a Parkinson patient is consistent with the clinical evolution of PDD. The cognitive decline paired with visual hallucinations differentiates PDD from medication-induced psychosis. Differential diagnoses include medication-induced psychosis, dementia with Lewy bodies, and Alzheimer\u2019s disease with comorbid parkinsonism. A careful medication review, neuropsychological testing, and clinical history help guide the diagnosis. PDD is diagnosed when cognitive deficits and psychotic symptoms occur in the context of established Parkinson\u2019s disease. First-line management of cognitive symptoms in PDD is with cholinesterase inhibitors, with rivastigmine being specifically approved for this indication. Second-line options (if hallucinations are severe or the patient is intolerant) may include low-dose atypical antipsychotics such as clozapine or quetiapine, but they must be used with extreme caution due to potential worsening of motor symptoms. In pregnancy/lactation, clinicians should weigh benefits against potential risks as data on cholinesterase inhibitors in these populations are limited. Option A (Rivastigmine) is correct because it effectively treats memory loss and hallucinations in PDD. Option B (Clozapine) is primarily an antipsychotic used for psychosis resistant to other treatments, but it does not improve memory and poses risks including agranulocytosis. Option C (Quetiapine) is sometimes used off-label for psychosis in Parkinson\u2019s disease, but again it does not address the cognitive decline. 1. Cholinesterase inhibitors are first-line for cognitive impairment in Parkinson\u2019s disease dementia. 2. Always review medications as drug-induced psychosis is an important differential. 3. Low-dose antipsychotics should be reserved for severe cases and used cautiously since they can worsen motor symptoms. Recent guidelines and studies continue to support the use of rivastigmine to improve cognitive function and reduce hallucinations in PDD. Ongoing research is focused on optimizing the balance between cognitive benefits and potential side effects in various populations.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with ataxia and optic atrophy, hearing loss, and slow saccades; what is the Dx?",
    "option_a": "Macchado joseph",
    "option_b": "SCA 6",
    "option_c": "SCA 7",
    "option_d": "NARP",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "The constellation of ataxia, visual impairment (presenting as optic atrophy from retinal degeneration), hearing loss, and slow saccades is characteristic of certain neurodegenerative disorders, particularly within the spinocerebellar ataxia (SCA) spectrum. SCA7 is uniquely recognized by the combination of progressive cerebellar ataxia and vision loss. SCA7 is caused by a CAG trinucleotide repeat expansion in the ATXN7 gene, leading to a polyglutamine expansion in the ataxin-7 protein. This mutation results in a toxic gain of function, which progressively damages the cerebellum and retina. As the retinal degeneration advances, patients may eventually develop optic nerve pallor (or atrophy) and may also manifest other ocular motor abnormalities such as slow saccades. Hearing loss has been reported in some cases, likely due to widespread neurodegeneration. The described clinical features\u2014progressive ataxia, visual decline (manifesting as optic atrophy secondary to retinal degeneration), hearing loss, and slow saccadic movements\u2014are most consistent with SCA7. This syndrome typically presents in mid-adult life with these hallmark features, distinguishing it from other SCAs with more restricted neurological signs. The differential diagnosis includes: (1) Machado-Joseph disease (SCA3), which has broader extrapyramidal features but less pronounced visual involvement; (2) SCA6, typically presenting with pure cerebellar ataxia without significant ophthalmologic findings; and (3) NARP, a mitochondrial disorder with a different inheritance pattern and typically earlier onset accompanied by retinitis pigmentosa rather than optic atrophy. Genetic testing is the definitive diagnostic tool to confirm the specific SCA subtype. There is no disease\u2010modifying treatment for SCA7; management is supportive and focuses on symptomatic care. Rehabilitation therapies (physical, occupational, and vision rehabilitation) are essential. Genetic counseling is recommended given its autosomal dominant inheritance. Pregnancy and lactation considerations are centered around providing accurate genetic counseling and discussion of recurrence risks since no specific prenatal therapy exists. Option A (Machado-Joseph disease/SCA3) typically presents with ataxia and sometimes oculomotor abnormalities but lacks the pronounced visual degeneration seen in SCA7. Option B (SCA6) is usually a purer form of cerebellar ataxia without significant optic nerve involvement. Option C (SCA7) is correct as it explains the combination of cerebellar ataxia, visual decline (retinal degeneration leading to optic atrophy), hearing loss, and slow saccades. Option D (NARP) usually presents with neuropathy, ataxia, and retinitis pigmentosa with a mitochondrial inheritance pattern, making it less consistent with the described presentation. 1. SCA7 is the only SCA prominently associated with visual loss due to retinal degeneration. 2. Slow saccades are an early ocular motor sign in SCA7. 3. Genetic testing is crucial for distinguishing among the different SCA subtypes. Recent advances in genetic sequencing have greatly enhanced the accuracy of diagnosing SCA subtypes, including SCA7. Although current management remains supportive, ongoing research into molecular pathways may eventually lead to targeted therapies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "patient with essential tremor and asthma, what is the treatment:",
    "option_a": "Primidone",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor is a common movement disorder characterized by an action/postural tremor. The first-line treatments are beta-blockers (such as propranolol) or primidone. However, in patients with asthma, beta-blockers can precipitate bronchospasm, making primidone the treatment of choice. The pathophysiology of essential tremor is not completely understood but is believed to involve abnormal oscillatory activity in the cerebellothalamocortical circuits. Primidone, an anticonvulsant, is thought to reduce tremor amplitude through central nervous system depressant effects, although the exact mechanism remains unclear. Patients with essential tremor generally present with tremor during voluntary movements (writing, using utensils) or when maintaining a posture. In individuals with coexisting asthma, beta-blockers are contraindicated due to the risk of bronchospasm. Hence, primidone serves as an effective alternative. The diagnosis of essential tremor is clinical, based on the history and examination. Differential diagnoses include Parkinson\u2019s disease (which typically presents with rest tremor and other motor deficits) and enhanced physiologic tremor (often related to anxiety or medication effects). The absence of additional neurological signs helps confirm essential tremor. The first-line treatment for essential tremor is beta-blockers (e.g., propranolol); however, in patients with contraindications such as asthma, primidone is recommended as the alternative first-line therapy. If primidone is not effective or not tolerated, other agents such as topiramate or gabapentin may be considered. In pregnancy and lactation, careful consideration is needed: both beta-blockers and primidone have potential risks, and treatment should be individualized with a discussion of risks versus benefits, though in asthmatic patients, beta-blockers remain contraindicated. Option A (Primidone) is correct because it is effective for essential tremor and is particularly indicated in patients with asthma to avoid bronchoconstriction from beta-blockers. Although beta-blockers (not listed in the options) are generally first-line, they are contraindicated in this patient population. 1. Essential tremor is best managed with beta-blockers, but primidone is the treatment of choice in patients with asthma. 2. The tremor in essential tremor is typically action- or postural-induced. 3. A careful drug history and comorbidity review are essential in choosing the appropriate therapy. Recent guidelines and clinical studies continue to support the use of primidone as an effective alternative to beta-blockers in patients with essential tremor who have contraindications to beta-blockade. Ongoing research is focused on understanding the underlying mechanisms and optimizing treatment strategies in special populations.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Hemifacial spasm treatment?",
    "option_a": "Botox",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Hemifacial spasm is a focal movement disorder characterized by involuntary, intermittent contractions of the muscles innervated by the facial nerve, typically starting around the eye and then involving other facial muscles. The syndrome is most commonly due to vascular compression of the facial nerve at its root exit zone, leading to focal demyelination and hyperexcitability with aberrant transmission. Botulinum toxin (Botox) acts by blocking the presynaptic release of acetylcholine at the neuromuscular junction, thereby reducing muscle activity and spasm. Patients present with unilateral twitching or spasms that can worsen with fatigue or stress. The condition\u2019s progression is usually gradual, and its social and cosmetic impact often prompts treatment. Diagnosis is based largely on clinical history and physical examination. Neuroimaging (typically MRI) is used to exclude secondary causes such as tumors, demyelination, or other structural lesions. Differential diagnoses include blepharospasm and facial dystonias. First-line treatment is botulinum toxin injections, which are typically repeated every 3\u20134 months. In refractory or severe cases, microvascular decompression surgery may be considered. In pregnant or lactating patients, the safety of botulinum toxin is not definitively established; therefore, careful risk\u2013benefit analysis and multidisciplinary consultation are advised. Option A (Botox) is correct because it is the established, first-line treatment for symptomatic relief in hemifacial spasm. No other options were provided, but alternatives such as microvascular decompression exist for refractory cases. 1. Hemifacial spasm usually begins with orbicularis oculi involvement and then spreads peripherally. 2. Botulinum toxin injections are effective in reducing spasm frequency and severity, significantly improving quality of life. Recent studies and clinical guidelines continue to endorse botulinum toxin injections as the standard therapy for hemifacial spasm, with ongoing refinements in injection techniques and toxin formulations further optimizing patient outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Female patient has tremor and her father has tremor, the father reported that his tremor is improved with wine. What is the Dx?",
    "option_a": "Essential tremor.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor is a common, often familial, movement disorder marked by an action or postural tremor, typically affecting the hands and arms and sometimes the head and voice. The precise mechanism of essential tremor is not fully elucidated but is thought to involve abnormal oscillatory activity in the cerebellothalamocortical circuits. A classic feature is improvement in tremor amplitude following the ingestion of a small amount of alcohol. A positive family history and tremor improvement with alcohol consumption are key clinical indicators of essential tremor. These features help differentiate it from other tremor disorders like Parkinson\u2019s disease, which typically presents with a resting tremor. The diagnosis is clinical, based on history and physical examination. Important differentials include Parkinson\u2019s disease (resting tremor, bradykinesia, rigidity) and dystonic tremor (irregular, task-specific). Diagnostic workup may include tremor analysis or, in uncertain cases, neuroimaging. First-line treatment options include beta-blockers (e.g., propranolol) and primidone. In patients who are pregnant or lactating, the choice of therapy must balance fetal and neonatal safety; some beta-blockers may be used cautiously under close supervision, while other medications might be avoided. Lifestyle modifications and adaptive strategies are also beneficial. Option A (Essential tremor) is correct given the classical presentation of familial tremor with improvement after alcohol consumption, which is nearly pathognomonic for the condition. 1. A history of tremor improvement with even a small amount of alcohol is highly suggestive of essential tremor. 2. Family history is commonly present, underscoring the genetic predisposition of the disease. Recent guidelines emphasize a symptom\u2010targeted treatment approach for essential tremor with beta-blockers and primidone as first-line agents, with ongoing research into additional pharmacologic and non-pharmacologic therapies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "orthostatic tremor not tolerating clonazepam, what is the treatment?",
    "option_a": "Propranolol",
    "option_b": "Levodopa",
    "option_c": "Pramipexol",
    "option_d": "Trihexiphenedyl",
    "option_e": "",
    "correct_answer": "Gabapentin (not listed)",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a rare movement disorder characterized by high-frequency tremor in the legs when standing, leading to a sensation of unsteadiness which often improves when sitting or walking. The disorder is thought to arise from aberrant neural oscillations involving cerebellar and brainstem circuits. Clonazepam, a benzodiazepine that enhances GABAergic transmission, is the first-line treatment; however, some patients may not tolerate it, necessitating alternative therapies such as gabapentin, which modulates neuronal excitability. Patients typically report rapid onset of leg tremor and instability upon standing, which may lead to falls. Diagnosis is supported by electromyography (EMG), which reveals a characteristic high-frequency tremor. Differential diagnoses include essential tremor (usually presenting with an action tremor of the hands), Parkinson\u2019s disease (resting tremor with bradykinesia), and peripheral neuropathic tremors. EMG is the key diagnostic tool that distinguishes orthostatic tremor by its high frequency (13\u201318 Hz) during standing. The first-line management is clonazepam. In patients who cannot tolerate clonazepam, gabapentin is considered the next best alternative based on clinical experience and smaller studies. For pregnant or lactating women, both clonazepam (FDA category D) and gabapentin (FDA category C) carry potential risks, and treatment decisions should involve a careful risk\u2013benefit analysis in consultation with neurology and obstetric specialists. Option A (Propranolol) is generally used in essential tremor rather than orthostatic tremor. Option B (Levodopa) is indicated for Parkinson\u2019s disease. Option C (Pramipexole) is a dopamine agonist used primarily in Parkinson\u2019s and restless legs syndrome, and Option D (Trihexyphenidyl) is an anticholinergic used in Parkinsonian tremor. None of these options are appropriate for orthostatic tremor, making gabapentin (although not listed) the correct choice. 1. Orthostatic tremor is best diagnosed with surface EMG, which shows a high-frequency tremor unique to the condition. 2. When patients are intolerant to clonazepam, gabapentin offers a viable alternative, even though its use is supported primarily by smaller studies and clinical experience. Emerging literature supports the use of gabapentin as an effective alternative in patients with orthostatic tremor who are unable to tolerate clonazepam. However, larger randomized controlled trials are needed to further establish its efficacy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "in PSP, senimit will improve?",
    "option_a": "Rigidity.",
    "option_b": "Bradykinesia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder classified within the atypical parkinsonian syndromes. It is characterized by early postural instability, gaze palsy (especially vertical), and parkinsonian features. PSP is associated with the accumulation of tau protein in the brain, leading to neurodegeneration in the brainstem, basal ganglia, and frontal cortex. This results in symptoms such as rigidity, bradykinesia, and impaired oculomotor function. Levodopa (Sinemet) can sometimes exert modest dopaminergic effects by improving pallidal\u2013striatal circuit function, especially impacting rigidity. Patients with PSP typically present with early falls, gait instability, and vertical gaze palsy. While levodopa is the mainstay treatment in Parkinson\u2019s disease, its benefit in PSP is limited; however, a subset of patients may experience mild improvement in rigidity. Diagnosis is clinical, supported by imaging studies (MRI may show midbrain atrophy giving a \u2018hummingbird sign\u2019). Differential diagnoses include idiopathic Parkinson\u2019s disease (which typically has a better levodopa response), multiple system atrophy, and corticobasal degeneration. Management of PSP is primarily supportive. A trial of levodopa is recommended, even though the response is usually modest and primarily limited to some improvement in rigidity. Other management strategies include physical therapy, occupational therapy, and speech therapy. In pregnant or lactating patients, levodopa is generally considered relatively safe (pregnancy category C) but should be used with caution after weighing the benefits against potential risks. Option A (Rigidity) is correct because, in PSP, if any benefit is observed with levodopa (Sinemet), it tends to be in the reduction of rigidity rather than improvements in bradykinesia, postural instability, or ocular motor dysfunction. The other options provided are either not specified or do not reflect the known limited responsiveness of PSP symptoms. 1. PSP patients show a poor overall response to dopaminergic therapies, with only a small subset demonstrating modest improvement in rigidity. 2. Early falls and vertical gaze palsy are key clinical indicators that differentiate PSP from idiopathic Parkinson\u2019s disease. Recent research and clinical guidelines reiterate the limited efficacy of levodopa in PSP but acknowledge that a trial is warranted to assess any potential benefit\u2014typically confined to rigidity\u2014with most patients requiring supportive and multidisciplinary care.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Parkinson patient on medication developed wearing off phenomena; what is the mechanism?",
    "option_a": "Failure medication",
    "option_b": "Disease prgression",
    "option_c": "medication intolerance",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "The wearing-off phenomenon in Parkinson\u2019s disease refers to the gradual shortening of the drug-effect period after each dose of levodopa. As the disease advances, the patient experiences a return of motor symptoms before the next scheduled dose. This effect is primarily due to disease progression. Progressive loss of dopaminergic neurons in the substantia nigra decreases the capacity to store dopamine, leading to fluctuations in response. In early disease stages, dopaminergic terminals buffer levodopa\u2019s fluctuations, but as neuronal loss increases, this buffering capacity diminishes. Patients report a re-emergence of parkinsonian features\u2014tremor, rigidity, and bradykinesia\u2014towards the end of a dosing interval. Recognizing the wearing-off phenomenon is integral to adjusting therapy in advanced Parkinson\u2019s disease. The diagnosis relies on a detailed clinical history and observation of symptom fluctuations relative to dosing times. Differential diagnoses include peak-dose dyskinesia (involuntary movements at the peak of the dose effect) and medication-induced adverse effects. Careful history taking and timing of symptoms help distinguish these conditions. First-line management includes optimizing the dosing regimen of levodopa by shortening the interval between doses or using controlled-release formulations. Adjunctive agents such as dopamine agonists, MAO-B inhibitors (e.g., rasagiline), or COMT inhibitors (e.g., entacapone) may help smooth out the response. In pregnancy and lactation, levodopa remains the mainstay of therapy; however, any adjunctive therapy must be carefully considered, weighing the risks and benefits based on current safety guidelines. Option A (Failure medication) is misleading because it implies a drug-related defect rather than a progression of the disease. Option C (Medication intolerance) suggests adverse effects unrelated to dosing fluctuations. Option B (Disease progression) correctly identifies the underlying mechanism affecting dopamine buffering. 1. Wearing-off phenomena are a hallmark of advancing Parkinson\u2019s disease. 2. Adjustments in dosing strategy can mitigate motor fluctuations. 3. Adjunct therapies may extend the benefit of levodopa in later stages. Recent studies and updated guidelines support the use of adjunctive pharmacotherapies to prolong levodopa\u2019s effect as the disease progresses. The emphasis remains on individualized treatment adjustments as dopaminergic neuron loss advances.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Sydenham chorea in girl:",
    "option_a": "ASO Titer",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a neurological manifestation seen in the context of acute rheumatic fever, typically affecting children and adolescents following a group A streptococcal infection. It is believed to stem from an autoimmune reaction in which antibodies directed against streptococcal antigens cross-react with basal ganglia tissue, leading to the characteristic involuntary movements. An elevated ASO (anti-streptolysin O) titer supports a recent streptococcal infection. Clinically, patients present with rapid, irregular, and purposeless movements, often accompanied by emotional lability. A history of sore throat and other rheumatic manifestations further supports the diagnosis. Diagnosis is based on clinical findings, a history of a recent streptococcal infection, and laboratory evidence (with elevated ASO titers as a key marker). Differential diagnoses include other causes of chorea such as Huntington disease, Wilson\u2019s disease, and drug-induced chorea. The timing and associated history are critical for proper differentiation. Management involves antibiotic therapy (e.g., penicillin) to eradicate any residual group A streptococcal infection and to provide prophylaxis against recurrence. Symptomatic treatment may be required for severe cases. Both penicillin and supportive care measures are considered safe in pregnancy and lactation, with penicillin being the gold standard for prophylaxis. Option A (ASO Titer) is correct because it is a valuable diagnostic indicator of a recent streptococcal infection, which is central to the diagnosis of Sydenham chorea. Other options were not provided but would not replace the utility of this laboratory measure. 1. Sydenham chorea is a post-streptococcal autoimmune phenomenon. 2. Elevated ASO titers are a key diagnostic clue. 3. It is part of the major criteria for diagnosing acute rheumatic fever. Current guidelines and recent research continue to emphasize the role of ASO titers in diagnosis along with the importance of penicillin prophylaxis to prevent recurrence of rheumatic fever-related complications.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Sydenham Chorea treatment:",
    "option_a": "Haloperidol",
    "option_b": "Valproic Acid",
    "option_c": "Carbamazepine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is characterized by involuntary, rapid movements caused by an autoimmune reaction in the basal ganglia, triggered by a prior group A streptococcal infection. Symptomatic treatment is often necessary when the chorea is severe or functionally impairing. The pathogenesis involves antibody-mediated inflammation of the basal ganglia. Haloperidol, a potent dopamine receptor blocker, helps by dampening the hyperkinetic movements associated with chorea. Patients, often children or adolescents, present with abrupt onset of involuntary movements, emotional lability, and muscle weakness. The severity of these symptoms determines the need for pharmacological intervention. Diagnosis is clinical, supported by a history of recent streptococcal infection and laboratory evidence (e.g., elevated ASO titers). Differential diagnoses include other movement disorders such as drug-induced chorea, lupus-associated chorea, and metabolic disorders. Detailed history and laboratory investigations help differentiate these conditions. Initial management focuses on symptomatic control. First-line agents include dopamine receptor antagonists such as haloperidol. Alternatives like valproic acid or carbamazepine can be considered in cases of contraindications or side effects. In pregnancy, while haloperidol can be used if necessary, careful risk-benefit assessment is essential due to potential neonatal extrapyramidal effects; non-pharmacologic support and close observation are also important. Option A (Haloperidol) is correct because it has been historically and effectively used to control the choreiform movements in Sydenham chorea. Although alternatives exist (such as valproic acid and carbamazepine), haloperidol remains a standard symptomatic therapy in severe cases. 1. Sydenham chorea is an autoimmune sequela of streptococcal infection. 2. Haloperidol is effective for severe chorea but alternatives exist if side effects occur. 3. Supportive care and secondary prophylaxis with antibiotics are essential. Recent studies have shown that while haloperidol is effective, treatment must be individualized. Emerging data supports the use of other agents such as valproate with similar efficacy and potentially fewer adverse effects. Guideline updates advocate a personalized approach based on severity and patient-specific factors.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Who will benefit from dopamine agonist more than L dopa?",
    "option_a": "Juvenile Parkinsonism",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Dopamine agonists mimic the effects of dopamine by stimulating dopamine receptors. They are often used as first-line treatment in younger Parkinson\u2019s disease patients to delay the introduction of levodopa, thereby reducing the risk of levodopa-induced motor complications. In juvenile Parkinsonism, the neurodegenerative process leads to dopamine deficiency. Dopamine agonists provide continuous receptor stimulation, and in younger patients whose nervous systems are more susceptible to developing fluctuations and dyskinesias, they help in reducing long-term side effects associated with levodopa. Patients with juvenile or early-onset Parkinsonism typically experience a prolonged disease course. Using dopamine agonists early in the treatment algorithm helps delay levodopa-associated complications, such as dyskinesias and motor fluctuations. Diagnosis of Parkinson\u2019s disease in younger patients is based on clinical findings, supplemented by imaging if needed. Differential considerations include drug-induced parkinsonism, Wilson\u2019s disease, or atypical parkinsonisms. A detailed history and neurological examination guide the diagnosis. Based on current guidelines, the first-line management for young-onset Parkinson\u2019s disease involves using dopamine agonists (e.g., pramipexole, ropinirole) to provide symptomatic control while delaying the need for levodopa. As the disease advances, a combination therapy may be necessary. In pregnant or lactating patients, treatment requires careful consideration; levodopa is generally preferred due to more extensive safety data, and dopamine agonists are used with caution given limited safety information in these populations. Option A (Juvenile Parkinsonism) is correct because younger patients benefit more from dopamine agonists due to their lower risk of developing levodopa-induced motor complications. Other hypothetical options were not provided, but the emphasis on age-related responsiveness makes juvenile parkinsonism the ideal group for this strategy. 1. Early use of dopamine agonists in young patients can significantly delay the onset of levodopa-induced dyskinesias. 2. Juvenile Parkinsonism requires a tailored treatment approach due to its longer course. 3. In pregnancy, levodopa remains the safer option based on current safety data. Recent clinical trials and updated guidelines recommend dopamine agonists as initial therapy in young-onset Parkinson\u2019s disease to mitigate motor complications. Ongoing research continues to refine strategies to balance efficacy with long-term side effects, emphasizing individualized treatment plans.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "They brought scenario from description it suggest dyt11 asking what is the type of myoclonus, her father has similar condition that improves with alcohol",
    "option_a": "(Essential myoclonus) is correct because the clinical scenario\u2014hereditary myoclonus with improvement on alcohol\u2014is characteristic of DYT11 myoclonus",
    "option_b": "(Cortical myoclonus) is incorrect; cortical myoclonus is typically associated with cortical excitability, stimulus sensitivity, and EEG abnormalities, and does not demonstrate the same degree of alcohol responsiveness. The marked answer (B) is therefore incorrect.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Myoclonus refers to sudden, brief, involuntary jerks of a muscle or group of muscles. In the context of DYT11 myoclonus-dystonia, the phenomenon is best characterized as an 'essential myoclonus'\u2014a type that arises from subcortical dysfunction and is notable for its improvement with alcohol intake. This contrasts with cortical myoclonus, which is often stimulus-sensitive and not typically modified by alcohol. DYT11 myoclonus-dystonia is linked to mutations in the SGCE gene, leading to impaired function in subcortical structures such as the basal ganglia and cerebellum. The improvement seen with alcohol is thought to be due to enhanced GABAergic modulation, which temporarily stabilizes the abnormal neuronal firing patterns that underlie the myoclonic jerks. Patients with DYT11 typically present with a combination of myoclonus and dystonia, often with a family history of similar symptoms. The hallmark feature of alcohol responsiveness helps differentiate this entity from other forms of myoclonus, such as cortical myoclonus, which generally exhibit different triggers and electrophysiological findings. Diagnosis is largely clinical and supported by a detailed family history, examination, and electrophysiological studies. Genetic testing for SGCE mutations can confirm the diagnosis. Differentials include cortical myoclonus (which shows EEG abnormalities and stimulus sensitivity) and other genetic movement disorders. Management is symptomatic. First-line treatments include benzodiazepines (e.g., clonazepam), antiepileptic medications (e.g., levetiracetam), and sometimes alcohol is self-reported to provide benefit. In refractory cases, deep brain stimulation (DBS) targeting the globus pallidus internus may be considered. In pregnancy and lactation, medication choices must balance symptom control with fetal safety \u2013 for instance, benzodiazepines are used at the lowest effective dose and only if clearly needed. Option A (Essential myoclonus) is correct because the clinical scenario\u2014hereditary myoclonus with improvement on alcohol\u2014is characteristic of DYT11 myoclonus-dystonia. Option B (Cortical myoclonus) is incorrect; cortical myoclonus is typically associated with cortical excitability, stimulus sensitivity, and EEG abnormalities, and does not demonstrate the same degree of alcohol responsiveness. The marked answer (B) is therefore incorrect. 1. DYT11 myoclonus-dystonia often presents with a family history and marked alcohol responsiveness. 2. Electrophysiological studies and genetic testing (SGCE mutation) aid in the diagnosis. 3. Management is largely symptomatic, with deep brain stimulation as an option for refractory cases. Recent research reinforces the role of SGCE mutations in DYT11 and underscores the benefits of DBS in refractory myoclonus-dystonia. Ongoing studies are exploring newer pharmacological agents that modulate GABAergic transmission without significant sedative effects, especially relevant for patient populations such as pregnant women where drug safety is paramount.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Typical scenario of left hemifacial spasm whats the tx",
    "option_a": "(Botulinum toxin) is correct and is supported by substantial evidence from clinical trials. Other options, such as anticonvulsants or surgical decompression, are either less effective or reserved for refractory cases. The marked answer (A) is consistent with current guidelines.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Hemifacial spasm is characterized by involuntary, intermittent contractions of the muscles innervated by the facial nerve. The condition is usually unilateral and often results from aberrant nerve activity due to vascular compression at the root exit zone. The primary mechanism involves the compression of the facial nerve by an aberrant or tortuous vascular loop, leading to demyelination and subsequent hyperexcitability of the nerve. This results in ectopic generation of action potentials, which manifest clinically as involuntary muscle contractions. Patients typically experience twitching that starts around the eye (orbicularis oculi) and may spread to involve other facial muscles. This can lead to significant social embarrassment and functional impairment. The condition must be differentiated from similar disorders such as focal seizures or blepharospasm. Diagnosis is based on clinical history and examination. MRI can be used to visualize neurovascular compression. Differential diagnoses include blepharospasm (which is usually bilateral and lacks evidence of nerve compression) and partial motor seizures. Botulinum toxin injections are the first-line treatment and work by inhibiting acetylcholine release at the neuromuscular junction, thereby reducing muscle contractions. In cases refractory to injections, surgical options such as microvascular decompression may be considered. In pregnant or lactating patients, botulinum toxin administration should be approached cautiously; while data are limited, it has been used in low doses when the benefits outweigh the risks. Option A (Botulinum toxin) is correct and is supported by substantial evidence from clinical trials. Other options, such as anticonvulsants or surgical decompression, are either less effective or reserved for refractory cases. The marked answer (A) is consistent with current guidelines. 1. Botulinum toxin injections provide significant symptomatic relief in hemifacial spasm. 2. MRI evaluation is important to rule out secondary causes. 3. Microvascular decompression is a surgical option for those who fail conservative management. Recent meta-analyses and randomized controlled trials have reaffirmed the efficacy and safety profile of botulinum toxin for hemifacial spasm. Ongoing studies are further elucidating optimal dosing intervals and techniques to minimize adverse effects, with particular consideration to vulnerable populations including pregnant women.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "MSA scenario asking about radiological findings",
    "option_a": "(Hot cross bun sign) is the correct radiological finding in MSA, especially for the cerebellar subtype. Other signs, such as the putaminal rim sign, are less specific, and signs like the hummingbird sign are typically associated with progressive supranuclear palsy (PSP). The marked answer (A) is therefore correct.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Multiple system atrophy (MSA) is a progressive neurodegenerative disorder presenting with a combination of parkinsonian, cerebellar, and autonomic features. An important radiological marker in MSA, particularly in the cerebellar subtype (MSA-C), is the 'hot cross bun' sign. The 'hot cross bun' sign represents a cruciform T2 hyperintensity in the pons, which results from selective degeneration of the pontocerebellar fibers. This finding helps differentiate MSA from other neurodegenerative disorders that affect the basal ganglia or brainstem. Patients with MSA may present with a constellation of symptoms including autonomic dysfunction (e.g., orthostatic hypotension), parkinsonian features (e.g., bradykinesia, rigidity), and cerebellar signs (e.g., ataxia). The presence of the hot cross bun sign on MRI supports a diagnosis of MSA, particularly of the cerebellar type. When evaluating a patient with parkinsonian features, differentials include Parkinson\u2019s disease, progressive supranuclear palsy, and corticobasal degeneration. MRI findings such as the hot cross bun sign help narrow the diagnosis to MSA. Other radiological signs like the putaminal rim sign (more common in MSA-P) may also be considered but are less specific. Currently, there is no cure for MSA and management is largely symptomatic. Treatment strategies include managing parkinsonian features with medications like L-dopa (although benefit is limited), addressing autonomic dysfunction with agents such as midodrine or fludrocortisone, and supportive therapies. In pregnancy, management options are further limited; careful dose adjustments and multidisciplinary care are required to balance maternal and fetal health. Option A (Hot cross bun sign) is the correct radiological finding in MSA, especially for the cerebellar subtype. Other signs, such as the putaminal rim sign, are less specific, and signs like the hummingbird sign are typically associated with progressive supranuclear palsy (PSP). The marked answer (A) is therefore correct. 1. The hot cross bun sign is a key MRI finding that points toward MSA-C. 2. Differentiation from other parkinsonian syndromes is aided by combining clinical features with neuroimaging findings. 3. Symptomatic management remains the mainstay of treatment in MSA. Current guidelines underscore the importance of MRI biomarkers in the diagnostic work-up of MSA. Ongoing research is focused on identifying disease-modifying therapies, though at present management is primarily supportive.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "L-dopa in PSP treat what",
    "option_a": "nalysis provided, both A and B are appropriate answers.",
    "option_b": "(Rigidity) is also correct for similar reasons. Option C (Gait instability) is incorrect because this symptom is primarily due to non",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A and B",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive supranuclear palsy (PSP) is an atypical parkinsonian disorder that presents with a range of motor symptoms including bradykinesia, rigidity, and gait disturbances along with characteristic ocular findings. L-dopa is used to address some parkinsonian features, though its benefits are typically limited in PSP. PSP is characterized by the accumulation of tau protein leading to neuronal degeneration in the basal ganglia, brainstem, and other regions. The dopaminergic pathways are affected, which contributes to symptoms such as bradykinesia and rigidity. However, the degeneration in non-dopaminergic structures, including those involved in postural control, makes symptoms like gait instability less responsive to dopamine replacement. Patients with PSP demonstrate a variable response to L-dopa. While bradykinesia and rigidity (related to nigrostriatal dopamine deficiency) may show modest improvement with L-dopa, gait instability and postural dysfunction\u2014stemming from broader brainstem and cerebellar involvement\u2014do not typically respond. PSP should be differentiated from Parkinson\u2019s disease and other atypical parkinsonian disorders. A trial of L-dopa is sometimes used diagnostically: a partial response (improvement in bradykinesia and rigidity) favors PSP over classical Parkinson\u2019s disease (which usually has a more robust response), though the overall benefits in PSP remain limited. Management of PSP is largely supportive. A trial of L-dopa may be warranted to improve motor symptoms such as bradykinesia and rigidity (first-line symptomatic treatment), but patients should be counseled regarding the limited improvement in axial symptoms and gait instability. In pregnancy and lactation, the use of dopaminergic therapy, including L-dopa, needs careful risk-benefit consideration, as high doses may pose risks; multidisciplinary consultation is advised. Option A (Bradykinesia) is correct, as L-dopa may have a modest beneficial effect on this symptom. Option B (Rigidity) is also correct for similar reasons. Option C (Gait instability) is incorrect because this symptom is primarily due to non-dopaminergic deficits and does not improve significantly with L-dopa. The marked answer only included A; however, based on current evidence and the option analysis provided, both A and B are appropriate answers. 1. PSP shows only limited improvement with L-dopa therapy, mainly affecting bradykinesia and rigidity rather than gait or balance. 2. A careful L-dopa trial can help differentiate PSP from other parkinsonian disorders. 3. Comprehensive management of PSP remains supportive. Recent studies confirm that the dopaminergic responsiveness in PSP is modest and predominantly impacts bradykinesia and rigidity. Emerging research continues to investigate additional therapeutic options targeting tau pathology, but current management guidelines remain focused on symptom control and supportive care.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario of Essential palatal myoclonus what to do",
    "option_a": "(MRI brain) is correct because it is the investigation of choice to rule out structural lesions within the Guillain",
    "option_b": "(EEG) is incorrect since palatal myoclonus is not an epileptic phenomenon. Option C (no mention of treatment) is not an acceptable approach because even if many cases are managed conservatively, symptomatic treatments exist and should be considered based on severity.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential palatal myoclonus is a movement disorder characterized by rhythmic, involuntary contractions of the palatal muscles. It is divided into two types: essential (idiopathic) and symptomatic (secondary to lesions in the Guillain-Mollaret triangle). The goal is to exclude any structural abnormalities that could be the cause. The symptomatic form of palatal myoclonus results from lesions in the dentato\u2010rubro\u2010olivary pathway (Guillain-Mollaret triangle) leading to aberrant rhythmic activity. In essential palatal myoclonus, no structural lesion is detected on imaging studies, suggesting a functional or idiopathic disruption in central motor regulation. Clinically, patients present with audible clicking sounds or palatal tremors that may be distressing. In symptomatic cases, additional neurological signs might be present, whereas the essential form tends to occur in isolation. Differentiation between the two influences treatment decisions as symptomatic cases require addressing the underlying lesion. The first step in the evaluation is neuroimaging \u2013 specifically, an MRI of the brain \u2013 to identify or exclude structural lesions in the Guillain-Mollaret triangle. Differential diagnoses include secondary causes like brainstem infarcts, multiple sclerosis, or tumors. EEG is not useful as the disorder is not epileptic. For essential palatal myoclonus, management is largely conservative and may include reassurance along with symptomatic treatments such as botulinum toxin injections if distressing. In symptomatic cases, treatment is directed toward the underlying disorder. In pregnant or lactating patients, the risks and benefits of any intervention (such as botulinum toxin) must be carefully weighed, although reassurance is usually preferred if no structural lesion is found. Option A (MRI brain) is correct because it is the investigation of choice to rule out structural lesions within the Guillain-Mollaret triangle. Option B (EEG) is incorrect since palatal myoclonus is not an epileptic phenomenon. Option C (no mention of treatment) is not an acceptable approach because even if many cases are managed conservatively, symptomatic treatments exist and should be considered based on severity. 1) Always rule out a structural lesion with an MRI when evaluating palatal myoclonus. 2) Essential palatal myoclonus is largely a diagnosis of exclusion with a normal MRI. 3) Treatment, if needed, focuses on symptomatic relief, often using botulinum toxin injections. Recent guidelines continue to endorse MRI as the first-line investigation to exclude secondary causes. Literature supports a conservative approach to essential palatal myoclonus with active treatment reserved for patients with significant symptoms.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Dyt11 what is the tx, he brought scenario suggestive improve with alcohol",
    "option_a": "(Clonazepam) is correct as it directly targets the underlying GABAergic dysfunction and has been well documented to improve both myoclonus and dystonia in DYT11. Alternatives such as levodopa or anticholinergics do not address the pathophysiological basis of DYT11 and have not demonstrated comparable efficacy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "DYT11, commonly known as myoclonus-dystonia, is a hereditary movement disorder characterized by a combination of myoclonic jerks and dystonia. A notable clue in its clinical presentation is the improvement of symptoms with alcohol intake. DYT11 is linked to mutations in the SGCE gene, affecting the function of proteins in basal ganglia and cerebellar circuits. The disorder\u2019s pathophysiology involves impaired GABAergic neurotransmission, which is why agents like clonazepam\u2014enhancing GABA-A receptor activity\u2014are effective. Patients typically present with myoclonic jerks that are often accompanied by dystonia, and most notably, experience symptom relief following alcohol consumption. This alcohol responsiveness is a key clinical hint that helps differentiate DYT11 from other movement disorders. The diagnosis is primarily clinical, supported by family history and genetic testing when available. Differential diagnoses include other forms of dystonia, myoclonic epilepsy, and other movement disorders that do not exhibit the characteristic improvement with alcohol. Clonazepam is considered first-line therapy given its efficacy in enhancing GABAergic inhibition and similarity to the symptomatic benefit provided by alcohol. In pregnant or lactating patients, the usage of clonazepam requires careful risk-benefit analysis due to potential teratogenicity and neonatal sedation; non-pharmacologic approaches should also be considered when appropriate. Other agents like anticholinergics have limited benefit and are not first-line. Option A (Clonazepam) is correct as it directly targets the underlying GABAergic dysfunction and has been well documented to improve both myoclonus and dystonia in DYT11. Alternatives such as levodopa or anticholinergics do not address the pathophysiological basis of DYT11 and have not demonstrated comparable efficacy. 1) Alcohol responsiveness is a hallmark of DYT11. 2) Clonazepam effectively mitigates symptoms due to its GABAergic mechanism. 3) Genetic confirmation (SGCE mutation) can support the clinical diagnosis if needed. Recent studies and treatment guidelines reaffirm clonazepam as the first-line pharmacotherapy for myoclonus-dystonia due to its established efficacy and mechanistic rationale. Ongoing research continues to evaluate alternative agents but has not displaced clonazepam as the preferred initial treatment.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Orthostatic tremor didn\u2019t response to clonazepam what\u2019s next",
    "option_a": "",
    "option_b": ", acknowledging that gabapentin is the appropriate therapeutic agent even if it is not explicitly listed.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor (OT) is a rare disorder characterized by high-frequency tremors predominantly affecting the legs upon standing, which leads to a sensation of unsteadiness and imbalance. It is distinct from other tremor disorders based on its specific clinical and electrophysiological profile. OT is thought to be due to abnormal oscillatory activity within central circuits, possibly involving the cerebellum and brainstem. Importantly, the pathogenesis does not implicate dopaminergic deficits, which is why treatments such as L-Dopa are ineffective. Patients report rapid, low-amplitude tremors in the legs that occur only when standing and typically subside with sitting or walking. This characteristic pattern helps differentiate OT from conditions like essential tremor or parkinsonian tremor. The definitive diagnosis of OT is achieved through neurophysiological studies, particularly surface electromyography (EMG), which demonstrates high-frequency oscillatory bursts typically in the range of 13\u201318 Hz. Differential diagnoses include essential tremor and anxiety-related tremors, which have different EMG findings and clinical courses. The first-line treatment for OT is typically clonazepam. When patients do not respond to clonazepam, gabapentin has been recognized as the next pharmacological option. In managing pregnant or lactating patients, both clonazepam and gabapentin require a careful evaluation of risks versus benefits; clonazepam carries a category D risk while gabapentin is generally category C, necessitating judicious use and close monitoring. Option A (L-Dopa) is incorrect because L-Dopa targets dopaminergic pathways, which are not implicated in OT, and clinical evidence shows poor response to this therapy. Option B, although not directly offering gabapentin as an option, correctly highlights that gabapentin is the next-line agent after the failure of clonazepam and its absence among the provided options underscores the gap. Therefore, the most accurate choice is Option B, acknowledging that gabapentin is the appropriate therapeutic agent even if it is not explicitly listed. 1) Orthostatic tremor is characterized by a high-frequency tremor (typically 13-18 Hz) on EMG. 2) Clonazepam is the first-line treatment, with gabapentin as the recommended second-line agent. 3) L-Dopa is ineffective in OT due to the non-dopaminergic nature of the disorder. Recent clinical reviews and small-scale studies have consistently demonstrated the limited role of dopaminergic drugs like L-Dopa in OT and have provided support for gabapentin's efficacy as a second-line treatment, reinforcing the current therapeutic algorithm.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Orthostatic tremor what is next investigation",
    "option_a": "(NCS/EMG) is correct because surface EMG is the definitive investigation to identify the high",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a distinctive movement disorder characterized by rapid, rhythmic muscle contractions in the legs that occur upon standing. This diagnosis requires confirmation through specialized neurophysiological studies. The underlying mechanism is believed to involve aberrant central oscillators, resulting in high-frequency tremors (typically 13\u201318 Hz) that are not present during rest or when the patient is seated. The disorder is not associated with peripheral neuropathy or dopaminergic deficits. Clinically, patients with OT present with a sensation of unsteadiness or shaking in the legs exclusively while standing. The tremor usually disappears once the patient sits or begins walking, making the condition unique among tremor disorders. The diagnostic study of choice is neurophysiological testing with nerve conduction studies (NCS) coupled with surface electromyography (EMG). EMG is especially valuable for recording the characteristic high-frequency tremor bursts. Differential diagnoses include other tremor syndromes such as essential tremor or parkinsonism, which can be distinguished by their different clinical presentations and EMG signatures. While the focus of this question is on the investigation aspect (i.e., NCS/EMG), the management following diagnosis typically follows a tiered approach. First-line treatment generally involves clonazepam; if ineffective, gabapentin is next. In pregnant or lactating women, both therapeutic agents require careful consideration of potential risks versus benefits, with non-pharmacologic management often preferred unless symptoms are severe. Option A (NCS/EMG) is correct because surface EMG is the definitive investigation to identify the high-frequency tremor bursts associated with OT. Other investigations such as MRI are primarily used to exclude secondary causes and are not diagnostic for OT by themselves. 1) EMG is crucial for confirming OT, with a typical tremor frequency of 13-18 Hz. 2) Clinical assessment alone can be insufficient for diagnosis; objective neurophysiological data is necessary. 3) Always rule out secondary etiologies with adjunct imaging when indicated. Current research and consensus guidelines continue to support the use of surface EMG as the gold standard for OT diagnosis. The characteristic high-frequency bursts provide both diagnostic clarity and help differentiate OT from other tremor disorders.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "What would response to dopamine agonist not L-dopa",
    "option_a": "(Aromatic decarboxylase",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Levodopa is the precursor to dopamine and must be converted to the active neurotransmitter to exert its effects, whereas dopamine agonists directly stimulate dopamine receptors without the need for conversion. Aromatic L\u2010amino acid decarboxylase (AADC) is an enzyme required to decarboxylate levodopa to produce dopamine. In conditions where AADC is deficient or inhibited, levodopa cannot be effectively converted, leading to poor symptomatic response. Dopamine agonists, on the other hand, bypass this enzymatic step by directly activating dopamine receptors, resulting in symptomatic relief. Clinically, patients who show a lack of response to levodopa but respond to dopamine agonists are suspected to have an issue with the levodopa conversion process. This scenario points toward a deficiency or functional impairment in AADC activity. The differential diagnosis in such scenarios includes conditions with enzyme deficiencies (e.g., AADC deficiency) versus disorders affecting dopamine metabolism. Diagnostic workup may include enzyme assays or genetic testing when AADC deficiency is suspected, and ruling out other metabolic disorders is essential. First-line management in patients with poor levodopa responsiveness due to AADC-related issues involves the use of dopamine agonists. In pregnancy and lactation, careful risk\u2013benefit analysis is essential; most dopamine agonists are categorized as pregnancy category B or C and must be used only if the potential benefits justify the potential risks. Option A (Aromatic decarboxylase \u2013 AADC) is correct because its deficiency directly explains the lack of conversion of levodopa to dopamine. Other enzyme targets such as monoamine oxidase or catechol-O-methyltransferase play roles in dopamine metabolism rather than the conversion process, and thus would not account for the observed differential response. 1. Levodopa requires conversion by AADC to become active. 2. Dopamine agonists directly stimulate receptors and are effective even when conversion is impaired. 3. Enzyme deficiencies should be considered when levodopa therapy is unexpectedly ineffective. Recent studies continue to reinforce the distinctive roles of L-dopa conversion and receptor stimulation. Current guidelines stress individualizing therapy based on the underlying pathophysiology, and research into enzyme deficiencies such as AADC deficiency is ongoing for better targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]